—Psoriasis drug candidate blocks inflammatory molecule “Pfizer’s candidate affects transcriptional activity of RORC2” In the roughly $11.5 billion market for psoriasis treatments, injectables and intravenous drugs get the most attention. A team of scientists at Pfizer is among those looking for an easier-to-take oral medication to tackle this inflammatory disease. The scientists report a small molecule (shown) that targets RORC2, a nuclear hormone receptor that in certain T cells stimulates the production of IL-17, an inflammatory cytokine (J. Med. Chem. 2018, DOI: 10.1021/acs.jmedchem.8b00392). Efforts to design molecules to block RORC2 activity have been hampered by its highly lipophilic ligand-binding domain.
by Megha Satyanarayana |
September 16, 2018